SERAPHIN血流动力学亚组研究:马西替坦对血流动力学和NT-proBNP的影响及其与疾病进展的关联
在SERAPHIN研究的187例基线及第6个月行右心导管检查的肺动脉高压患者中,马西替坦较安慰剂改善心脏指数、右心房压、平均肺动脉压、肺血管阻力和NT-proBNP。基线及第6个月的心脏指数、右心房压和NT-proBNP绝对水平(而非其变化)与发病率/死亡率事件相关,达到阈值者风险更低。
要点
- 马西替坦较安慰剂改善第6个月心脏指数、右心房压、平均肺动脉压、肺血管阻力及NT-proBNP。
- 基线及第6个月心脏指数、右心房压、NT-proBNP绝对水平与发病率/死亡率事件相关,变化值不相关。
- 第6个月心脏指数>2.5 L/min/m2、右心房压<8 mmHg或NT-proBNP<750 fmol/ml者发病率/死亡率风险更低。
核心结论
- 在所有治疗组中,基线及第6个月的心脏指数、右心房压和NT-proBNP值(而非其变化)与发病率/死亡率事件相关,证实这些参数在预测肺动脉高压患者疾病进展中的价值。
- 马西替坦通过改善上述参数,提高了达到与较低发病率/死亡率风险相关阈值的可能性。
研究设计与样本
- SERAPHIN研究是一项随机对照试验,共742例随机患者,其中187例在基线及第6个月行右心导管检查并参与血流动力学亚组研究。
- 预设终点包括基线至第6个月心脏指数、右心房压、平均肺动脉压、肺血管阻力、混合静脉血氧饱和度和NT-proBNP的变化。
- 探索性分析采用Kaplan-Meier法和Cox回归模型评估心脏指数、右心房压和NT-proBNP与疾病进展的关联。
- 主要终点为至首次发病率/死亡率事件的时间。
主要发现
- 第6个月时,马西替坦较安慰剂改善心脏指数、右心房压、平均肺动脉压、肺血管阻力和NT-proBNP。
- 第6个月时,心脏指数>2.5 L/min/m2者较未达到该阈值者发病率/死亡率风险更低(HR 0.49,95% CL 0.28-0.86)。
- 第6个月时,右心房压<8 mmHg者较未达到该阈值者发病率/死亡率风险更低(HR 0.72,95% CL 0.42-1.22)。
- 第6个月时,NT-proBNP<750 fmol/ml者较未达到该阈值者发病率/死亡率风险更低(HR 0.22,95% CL 0.15-0.33)。
关键数值与推荐
- 第6个月心脏指数>2.5 L/min/m2对应HR 0.49(95% CL 0.28-0.86)。
- 第6个月右心房压<8 mmHg对应HR 0.72(95% CL 0.42-1.22)。
- 第6个月NT-proBNP<750 fmol/ml对应HR 0.22(95% CL 0.15-0.33)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The effect of macitentan on haemodynamic parameters and NT-proBNP levels was evaluated in pulmonary arterial hypertension (PAH) patients in the SERAPHIN study. Association between these parameters and disease progression, assessed by the primary endpoint (time to first morbidity/mortality event), was explored. METHODS AND RESULTS: Of the 742 randomized patients, 187 with right heart catheterization at baseline and month 6 participated in a haemodynamic sub-study. Prespecified endpoints included change from baseline to month 6 in cardiac index (CI), right atrial pressure (RAP), mean pulmonary arterial pressure (mPAP), pulmonary vascular resistance (PVR), mixed-venous oxygen saturation, and NT-proBNP. Exploratory analyses examined associations between CI, RAP, and NT-proBNP and disease progression using the Kaplan-Meier method and Cox regression models. Macitentan improved CI, RAP, mPAP, PVR and NT-proBNP vs. placebo at month 6. Absolute levels of CI, RAP and NT-proBNP at baseline and month 6, but not their changes, were associated with morbidity/mortality events. Patients with CI > 2.5 L/min/m2, RAP < 8 mmHg, or NT-proBNP < 750 fmol/ml at month 6 had a lower risk of morbidity/mortality than those not meeting these thresholds (HR 0.49, 95% CL 0.28-0.86; HR 0.72, 95% CL 0.42-1.22; and HR 0.22, 95% CL 0.15-0.33, respectively). CONCLUSIONS: For all treatment groups, baseline and month 6 values of CI, RAP, and NT-proBNP, but not their changes, were associated with morbidity/mortality events, confirming their relevance in predicting disease progression in patients with PAH. By improving those parameters, macitentan increased the likelihood of reaching threshold values associated with lower risk of morbidity/mortality.
引用
- Galiè N, Jansa P, Pulido T, et al. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. Eur Heart J. 2017. PMID: 28329315. doi:10.1093/eurheartj/ehx025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。